secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2024-04-29T23:59:59+00:00
Accession:  0000950170-24-049436
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan Therapeutics hires Mary Kay Fenton as CFO; $495k salary, 200k-share option grant
--------------------------------------------------------------------------------

- Mary Kay Fenton appointed CFO effective April 29, 2024; previously CFO of Talaris Therapeutics.
- Annual base salary set at $495,000; target annual bonus of 40% of base salary.
- Received option to purchase 200,000 shares vesting over 4 years (25% one-year cliff).
- Severance: 9 months base salary plus prorated bonus if terminated without cause or for good reason outside CIC period.
- No familial relationship with directors/officers; at-will employment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000095017024049436/0000950170-24-049436-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000095017024049436/cgem-20240429.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-049436

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer